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Abstract
Introduction: A C-to-T single nucleotide polymorphism (SNP) located at position 1858 of human protein tyrosine
phosphatase, non-receptor type 22 (PTPN22) complementary DNA (cDNA) is associated with an increased risk of
systemic lupus erythematosus (SLE). How the overall activity of PTPN22 is regulated and how the expression of
PTPN22 differs between healthy individuals and patients with lupus are poorly understood. Our objectives were to
identify novel alternatively spliced forms of PTPN22 and to examine the expression of PTPN22 isoforms in healthy
donors and patients with lupus.
Methods: Various human PTPN22 isoforms were identified from the GenBank database or amplified directly from
human T cells. The expression of these isoforms in primary T cells and macrophages was examined with real-time
polymerase chain reaction. The function of the isoforms was determined with luciferase assays. Blood samples were
collected from 49 subjects with SLE and 15 healthy controls. Correlation between the level of PTPN22 isoforms in
peripheral blood and clinical features of SLE was examined with statistical analyses.
Results: Human PTPN22 was expressed in several isoforms, which differed in their level of expression and
subcellular localization. All isoforms except one were functionally interchangeable in regulating NFAT activity. SLE
patients expressed higher levels of PTPN22 than healthy individuals and the levels of PTPN22 were negatively
correlated with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage
Index (SLICC-DI).
Conclusions: The overall activity of PTPN22 is determined by the functional balance among all isoforms. The levels
of PTPN22 isoforms in peripheral blood could represent a useful biomarker of SLE.
Introduction
PTPN22 is a non-receptor type protein tyrosine phosphat-
ase expressed mainly in hematopoietic cells [1]. It contains
a basic bipartite nuclear localization signal (NLS) in its N-
terminus, which is followed by a conserved protein tyro-
sine phosphatase (PTP) domain. An inhibitory domain
inhibiting its phosphatase activity is located immediately
after the PTP domain [2]. Its C-terminal half is relatively
less conserved, with the exception of four proline-rich
domains. Its physiological function is still not fully
understood. PTPN22 has been shown to attenuate the
strength of T cell receptor (TCR) signals by interacting
with Lck, Csk, and Vav [3-6]. PTPN22-deficient mice
developed age-dependent splenomegaly due to hyper-
activation of lymphocytes, and knockdown of PTPN22 in
human T cells with small interfering RNA (siRNA) led to
enhanced TCR-mediated nuclear factor-kappa B (NF-κB)
activity [7,8]. PTPN22 is present in both the cytoplasm
and nucleus of macrophages [9]. Its nuclear localization
requires the NLS proximal to the PTP domain. The
expression of PTPN22 is further induced in alternatively
activated macrophages through a STAT6-dependent
mechanism. Cytoplasmic PTPN22 suppresses the pola-
rization of classically activated macrophages, whereas
nuclear PTPN22 promotes the differentiation of alterna-
tively activated macrophages [9].
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http://arthritis-research.com/content/16/1/R14Alternative splicing is an evolutionary conserved mech-
anism enabling a cell to produce proteins of different
function from a single gene. A large body of evidence has
indicated that the process of alternative splicing is corre-
lated with disease activity or is even pathogenic in some
autoimmune diseases [10-12]. At least two isoforms of
PTPN22 have been reported. Lyp2, of which the sequence
was deduced from two complementary DNA (cDNA)
fragments, lacks the three most C-terminal proline-
rich domains [1], whereas isoform 2, tentatively called
PTPN22.2 for the purpose of discussion, splices out exons
10 and 11. However, it is unclear whether Lyp2 and
PTPN22.2 are functionally distinct from the full-length
PTPN22 (tentatively called PTPN22.1). We have also
identified a novel isoform of PTPN22, called PTPN22.6,
which lacks nearly the entire PTP domain [13]. Unlike
PTPN22.1, overexpression of PTPN22.6 actually increased
NFAT-dependent luciferase activity. More importantly,
PTPN22.6 can act as a dominant negative mutant of
PTPN22.1 in regulating cytokine production in Th cells,
suggesting that the overall activity of PTPN22 can be
influenced by the relative levels of its isoforms.
Several genome-wide association studies have linked
PTPN22 to autoimmune diseases. A C-to-T single nu-
cleotide polymorphism, which is located at position
1858 of PTPN22 cDNA and converts an arginine to a
tryptophan, is associated with a higher risk of rheuma-
toid arthritis (RA), systemic lupus erythematosus (SLE),
and type 1 diabetes but reduces the risk of Crohn’s
disease [7,14-17]. Despite these observations, it is still
unclear whether the expression of PTPN22 in patients
with autoimmune diseases differs from that of healthy
individuals, and how this would occur. In addition, the
functional impact of the C1858T SNP is still controver-
sial and appears to be complicated. The conversion from
arginine to tryptophan resulted in both gain and loss of
function of PTPN22 in T cells in different studies
[18,19]. We also found that the R-to-W conversion in
the context of PTPN22.1 resulted in a gain of function
of PTPN22 and a reduction of interleukin (IL)-2 pro-
duction in T cells. In contrast, the R-to-W conversion in
the context of PTPN22.6 led to a loss of function of
PTPN22 and overproduction of IL-2 [13]. Thus, the
functional impact of the C1858T SNP is isoform
dependent. Furthermore, the C1858T SNP is associated
with a loss-of-function phenotype in resting macro-
phages but a gain of function in classically activated
macrophages [9]. How these C1858T SNP-associated
functional changes affect the risk of autoimmune di-
seases is largely unknown. We have previously shown
that the transcript level of PTPN22.6 but not total
PTPN22 in peripheral blood is correlated with the 28-
joint disease activity score with three variables including
C-reactive protein (DAS28-CRP3) scores in patients with
RA [13]. However, it is unclear whether the expression
of PTPN22 and its isoforms is altered in SLE patients
and whether the level of PTPN22 isoforms also is corre-
lated with disease activity of SLE.
Here we report the identification of additional iso-
forms of human PTPN22. We examined the expression
of the PTPN22 isoforms in primary human T cells and
macrophages. We further compared the expression of
PTPN22 isoforms in the peripheral blood of 15 healthy
donors and 49 SLE patients, and correlated the expres-
sion pattern of PTPN22 isoforms with clinical features
of lupus.
Methods
Human samples
Forty-nine individuals with SLE fulfilling the 1997
American College of Rheumatology revised classification
criteria [20] were previously recruited from the Lupus
Center of the Brigham and Women’s Hospital (BWH)
for the Lupus Biobank. Fifteen control samples from
healthy individuals without SLE or related connective
tissue disease were obtained from the PhenoGenetic
project at the same hospital. All study subjects con-
sented to participate in studies conducted through the
Lupus Biobank and the PhenoGenetic project, and
agreed to the publication of results derived from such
studies. Demographics were collected in addition to the
following data from all SLE cases: 1) age at SLE onset; 2)
SLE manifestations and organ involvement; 3) concur-
rent anti-double-stranded DNA antibody titer, C3 and
C4. The treating rheumatologist performed a history and
physical examination for SLE disease activity (Safety on
Estrogens in Lupus Erythematosus National Assessment-
SLE Disease Activity Index; SELENA-SLEDAI) [21], and
history and chart review to complete an SLE organ da-
mage assessment (SLICC-DI) [22]. Whole blood samples
in PAX gene tubes (Qiagen, Germantown, MD, USA)
were obtained from all subjects by standard antecubital
venipuncture and stored at -80C at the Broad Institute
of MIT and Harvard as separated whole blood or ex-
tracted RNA. All aspects of the study were approved by
the partners’ Institutional Review Board.
Preparation of human peripheral blood mononuclear cells
(PBMC) and helper T (Th) cells
PBMC were isolated from buffy coats. Th cells were
enriched from PBMC with CD4 Microbeads (120-000-
440, Miltenyi Biotec, Auburn, CA, USA). Macrophages
were prepared from PBMC according to a published
protocol [23].
Cell culture and medium
Human primary Th cells and Jurkat cells were cultivated
in RPMI-1640. In some experiments, Th and Jurkat cells
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(Hit3a, Cat. # 300314, BioLegend, San Diego, CA, USA)
and 2 μg/ml of soluble anti-CD28 (CD28.2, Cat. # 302914,
BioLegend) in the presence of IL-2 (50 unit/ml) for an in-
dicated amount of time. Human colonic adenocarcinoma
cell line HT-29 cells (HTB38, ATCC) and human em-
bryonic kidney cells 293 T were cultivated in McCoy’s5 A
medium (Gibco, Grand Island, NY, USA) and Dulbecco’s
modified Eagle’s medium (DMEM), respectively. Primary
human macrophages were stimulated with lipopolysac-
charide (LPS) (1 μg/ml, InvivoGen, San Diego, CA, USA)
along with human interferon-gamma (hIFN-γ) (50 ng/ml,
PeproTech, Rocky Hill, NJ, USA) for 24 hours for M1
polarization or hIL-4 (25 ng/ml, PeproTech) along with
hIL-13 (25 ng/ml, PeproTech) for 24 hours for M2
polarization.
Western blotting
Whole-cell extract was obtained by lysing cells with lysis
buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1%
TritonX-100, 0.5% DOC, 0.1% SDS, and 1 mM EDTA)
containing 0.5 mM PMSF and complete protease inhibi-
tor cocktail (Roche, Basel, Switzerland). Cytoplasmic and
nuclear extracts were prepared by washing cells with
cold phosphate- buffered saline (PBS) and resuspending
them in hypotonic lysis buffer (10 mM HEPES, pH7.9,
1 mM MgCl2, 10 mM KCl, 0.1% TritonX-100, 20%
Glycerol, 0.5 mM PMSF, and protease inhibitors) on
ice for 10 minutes. The supernatant, corresponding to
cytoplasmic fraction, was collected by centrifugation at
12,000 g for 10 minutes. The nuclear pellet was washed
with hypotonic lysis buffer and then resuspended in
hypertonic lysis buffer (10 mM HEPES, pH7.9, 400 mM
NaCl, 1 m EDTA, 0.1% TritonX-100, 20% Glycerol,
1 mM PMSF, and protease inhibitors) and then incu-
bated on ice for 20 minutes. Nuclear extract was
collected by centrifugation. Protein extract was analyzed
by immunoblot. The following antibodies were used:
human PTPN22 antibody AF3428 (R & D Systems,
Minneapolis, MN, USA), Hsp90 α/β (sc-7947) and
Lamin B (sc-6216) antibody (Santa Cruz Biotechnology,
Inc. Santa Cruz, CA, USA), Oct1 (sc-232, Santa Cruz
Biotechnology, Inc.), and FLAG antibody (F3165, Sigma-
Aldrich, St Louis, MO, USA).
Plasmid, transfection and luciferase assay
cDNAs encoding PTPN22.1 and PTPN22.8 were am-
plified directly from Jurkat cells with primers 5′-CG
GGATCCTTGCTCTGCAGCATGGACCAAAGA-3′ and
5′-GACGTCGACGCGTTTAAATATTCCAAGTTGGTG
GT-3′. cDNA clones BC071670 (PTPN22.2) and BC0
17785 (PTPN22.7) were purchased from Open Biosys-
tems (Huntsville, AL, USA). cDNA clones AK3030124
(PTPN22.4), AK310698 (PTPN22.5), and AK310570
(PTPN22.6) were obtained from the NITE Biological
Resource Center (Chiba, Japan). All cDNA fragments
were cloned into an N-terminal FLAG-tag expression
vector pCMV-Tag 2B (Stratagene, La Jolla, CA, USA).
Transfection of 293 T cells was performed with Effec-
tene Transfection Reagent (Cat. # 301427, Qiagen).
Transfection of Jurkat cells was performed with electro-
p o r a t i o nw i t haG e n eP u l s e rI I( B i o - R a d ,H e r c u l e s ,C A ,
USA) set at 374 V/1050 μF. In all NFAT luciferase
assays, Jurkat cells were transfected with 5 μgo f
3xNFAT-Luc, 0.5 μg pTK-Renilla, and 10 μgo fp C M V -
Tag 2B expression vectors; rested for 48 hours; and then
stimulated with anti-CD3 for 6 hours. Luciferase activity
was determined with a Dual-Luciferase™ Reporter Assay
S y s t e m( P r o m e g a ,M a d i s o n ,W I ,U S A ) .F i r e f l yl u c i f e r a s e
activity was then normalized against Renilla luciferase
activity obtained from the same sample. 3xNFAT-Luc
and pTK-Renilla lucifease vectors were described pre-
viously [24].
Real-time PCR and non-quantitative PCR
Total RNA was prepared using a Trizol Plus kit (Invitrogen,
Carlsbad, CA, USA). Reverse transcription was performed
on 1 ug of total RNA using the QuantiTect Reverse
Transcription kit (Qiagen). Real-time PCR analysis was
performed using the Brilliant SYBR Green QPCR kit
according to the manufacturer’s protocol (Stratagene) on
a MX-3000P apparatus (Stratagene). The cycling con-
ditions are: one cycle of 95C for 10 minutes and 40 cycles
of 95C for 30 seconds, 56C for 1 minute, and 72C for
1 minute. The following primer pairs were used: ‘total’
5′-GCAGAAGTTCCTGGATGAG-3′ and 5′-TCAGCCA
CAGTTGTAGGATAG-3′;L y p 25 ′-GTGGAACATCTGA
ACCAAAG-3′ and 5′-AGCCAAGAGAAATTTTTACCT
G-3′; PTPN22.2 5′-CCAAGAGGATGACAGTGTTC-3′
and 5′-CTTTGCTTGACTCCCATCTTTTA-3′; PTPN
22.5/6 5′-ATCTGTAATTCTTGCCCACC-3′ and 5′-CT
CTTCAGTAAAATAACACACATACC-3′; PTPN22.6 5′-
TTTGCCCTATGATTATAGCCG-3′ and 5′-GTTCTCA
GGAATTATAAGGACACT-3′; PTPN22.7/8 5′-TCTACA
ACCCTCCTGGACT-3′ and 5′-TTTCAGCTTCCTTTC
CCATT-3′; Ets-1(p51) 5′-CTCCTATGACAGCTTCGA
CT′3′ and 5′-ATCTCCTGTCCAGCTGATAA-3′; β-actin
5′-GTGACAGCAGTCGGTTGGAG-3′ and 5′-AGGAC
TGGGCCATTCTCCTT-3′. All real-time PCR reactions
were done in duplicate and the transcript levels were
normalized against those of β-actin.
siRNA transfection
One million Jurkat cells were resuspended with 400 ul
Opti-mem I containing 400 pmole of siRNA and sub-
jected to electroporation with a Gene Pulser II (Bio-Rad)
set at 250 V/400 uF. Human PTPN22 ON-TARGETplus
SMARTpool siRNA (L-008066-00-0005), ON-TARGETplus
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5′-UGGAAGAAUGGUUCGUUAAUU-3′; anti-sense: 5′-
UUAACGAACCAUUCUUCCAUU-3′)w e r ep u r c h a s e d
from Dharmacon/Thermo Scientific (Lafayette, CO, USA).
Statistical analysis
D’Agostino-Pearson omnibus normality test was used to
examine the normality of the data. Statistical analysis was
performed with paired Student’s t test (Figure 1C), one-
way ANOVA (Figures 1D and 3B), the Mann–Whitney
test (Figure 4), and Spearman correlation (Figure 5).
Results
Identification of additional PTPN22 isoforms
In addition to the published PTPN22 isoforms, we iden-
tified several cDNA sequences corresponding to three
Figure 1 (See legend on next page.)
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NCBI Gene database (Figure 1A). AK303124 is the pro-
duct of an out-of-frame splicing between exons 4 and 9.
It contains two open reading frames: one of 135 amino
acid residues and the other starting at a methionine of
exon 9 and corresponding to the last 563 amino acid
residues of the full-length PTPN22. AK310698 lacks
exon 21 but includes at its C-terminus eight novel
amino acid residues encoded by the genomic sequence
immediately 3′ to exon 20. BC017785 splices out exons
6 and 8 to 19. We tentatively named these three novel
isoforms PTPN22.4, PTPN22.5, and PTPN22.7. We also
amplified a novel isoform PTPN22.8 (GenBank accession
number JN084012), which lacks exon 6, directly from
Jurkat T cells. We were able to confirm the presence of
each of the unique or shared spliced junctions in human
primary T cells with real-time PCR and DNA sequencing
(Figure 1A and data not shown). In addition, we were
able to amplify the transcript of each of the isoforms ex-
cept Lyp2 in its entirety with PCR directly from Jurkat
cells. Several attempts to amplify the entire Lyp2 were
unsuccessful. The counterpart of PTPN22.2 is also
(See figure on previous page.)
Figure 1 Alternatively spliced forms of human protein tyrosine phosphatase, non-receptor type 22 (PTPN22). (A) Schematic diagrams of
the human ptptn22 gene and putative protein products of each isoform. Exons are numbered, and white boxes represent untranslated exons.
Green boxes represent nuclear localization signal (NLS). Yellow boxes represent the protein tyrosine phosphatase (PTP) domains. The key
catalytic region (HCSAGC) and R620 are marked. Silver boxes are inhibitory domains. Red boxes represent proline-rich regions. Two-headed
arrows indicate the real-time PCR products of the isoforms. The exons constituting each isoform are indicated. The GenBank accession numbers,
if available, are listed in parentheses. (B) 293 T cells were transfected with 1 μg of an expression vector expressing indicated FLAG-PTPN22 isoforms.
The protein levels of FLAG-PTPN22 isoforms and Hsp90 in the transfected cells were determined with Western blotting. (C).2 9 3Tc e l l sw e r et r a n s -
fected with a plasmid vector expressing FALG-PTPN22.1 and FLAG-PTPN22.6. The transfected cells were treated with 20 ug/ml of cycloheximide. The
levels of FLAG-PTPN22.1 and FLAG-PTPN22.6 were then determined with Western blotting and densitometry at indicated time points after the addition
of cycloheximide. The level at time 0 for each protein was arbitrarily set as 100%. Statistical significance was determined with paired Student’s t test. *P
<0.05; **P <0.005. (D) Jurkat cells were transfected with indicated siRNA. Cell extract of the transfect cells was then analyzed on Western blotting using
anti-PTPN22 and anti-Hsp90 (the left panel). Extract from 293 T cells transfected with an expression vector of Lyp2 was included in the Western blotting
(Lyp2 tx 293 T). The levels of the dominant 110 kD PTPN22 protein bands were quantified with a densitometer and normalized against the level of
Hsp90 from the corresponding samples, and are shown in the right panel. The normalized level of the mock-transfected cells was arbitrarily set as 100%.
Statistical analysis of three independent experiments was performed with one-way ANOVA followed by Tukey’st e s t .
Figure 2 Expression of protein tyrosine phosphatase, non-receptor type 22 (PTPN22) isoforms in human helper T (Th) cells and macrophages.
(A) RNA was prepared from human Th cells obtained from three healthy donors, which were stimulated in vitro with anti-CD3/anti-CD28 for indicated
periods of time and subjected to real-time PCR analysis with isoform-specific primers. Each real-time PCR reaction was done in duplicate. The transcript
levels thus obtained were normalized against those of β-actin from the same samples. The data shown are the means and standard deviations from
three donors. (B) Protein extract prepared from human Th cells described in A was subjected to Western blotting and probed with PTPN22 antibody
and Hsp90 antibody. (C) RNA was prepared from resting, M1, and M2 macrophages derived from peripheral blood of seven additional healthy donors
and subjected to real-time PCR analysis with isoform-specific primers.
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to NCBI Gene database, suggesting that these alternative
splicing events are evolutionarily conserved.
Not all of the isoforms can be expressed efficiently in
mammalian cells. We replaced the initiating methionine
of each isoform with a FLAG tag and expressed the
FLAG-fused PTPN22 proteins in 293 T cells. We found
that PTPN22.1 and Lyp2 were expressed more efficiently
than PTPN22.2, PTPN22.5, PTPN22.6, and PTPN22.8
(Figure 1B). No protein product of PTPN22.4, either
starting from the methionine in exon 1 (4.1) or exon 9
(4.2), or of PTPN22.7 was detected, suggesting that
PTPN22.4 and PTPN22.7 are non-productive. We there-
fore excluded these two isoforms from subsequent func-
tional analyses.
Despite the difference in the protein level, the tran-
script level of each isoform in transfected cells was very
comparable when measured with real-time PCR using a
pair of primers targeting the FLAG/PTPN22 fusion
junction that is common to all isoforms (data not
shown). As the transcripts of these FLAG-PTPN22 pro-
teins contain the same Kozak sequence, initiating ATG,
and 3′ polyadenylation tail, which are embedded in the
expression vector, we postulated that the difference in
the protein level was due to a difference in protein
stability instead of translational efficiency. To test this
hypothesis, we compared the protein stability between
PTPN22.1 and PTPN22.6, which was chosen as an ex-
ample because it was the least expressed but detectable
isoform. We treated transfected cells with cycloheximide
to stop protein synthesis and then compared the degra-
dation rate of FLAG-PTPN22.1 and FLAG-PTPN22.6.
PTPN22.1 protein was indeed more stable than
PTPN22.6 (Figure 1C).
We previously used a PTPN22.6-specific antibody to
demonstrate the presence of endogenous PTPN22.6 pro-
tein in human T cells. In addition, an anti-human poly-
clonal PTPN22 antibody, which was raised against S306-
S684 of PTPN22.1 and should recognize all isoforms,
detected one dominant broad protein band centering
around 110 kD and several smaller protein species in
Jurkat human T cells but not in HT-29 adenocarcinoma
cells, which do not express PTPN22 (Figure 1D and
[13]). The levels of almost all of the protein species were
reduced by PTPN22 siRNA but not by scrambled
siRNA. The commercially available PTPN22 siRNA
Figure 3 Subcellular localization and function of protein tyrosine phosphatase, non-receptor type 22 (PTPN22) isoforms. (A) 293 T cells
were transfected with 1 μg of plasmid vectors expressing indicated FLAG-tagged PTPN22 isoforms. Cytoplasmic and nuclear extract was
separately prepared from the transfected cells and subjected to Western blotting with indicated antibodies. The protein product of each
isoform is marked with ‘*’. (B) Jurkat cells were transfected with a NFAT-luc reporter, 10 ug of pCMV2B expressing indicated FLAG-PTPN22
isoforms, and a TK-Renilla reporter. The transfected cells were then stimulated with anti-CD3 overnight. A fraction of the transfected cells was subjected
to Western blotting with anti-FLAG (the top panel). The luciferase activity of the remaining cells was analyzed. Normalized firefly luciferase activity was
calculated as described in Methods and is shown in the bottom panel. In each experiment, the normalized value from cells transfected with the empty
expression vector was arbitrarily set as 100. The data shown are the means and standard deviations of three independent experiments. Statistical
significance was calculated with one-way ANOVA followed by Dunn’s test comparing non-full-length isoforms to PTPN22.1. *P=0.0158.
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lupus. (A and B) RNA was prepared from whole blood of healthy individuals (N=15) and patients with lupus described in Table 1. The RNA
was subjected to real-time PCR using PTPN22 isoform-specific primers. The transcript level thus obtained was normalized against that of β-actin
obtained from the same sample and is shown in A. The relative level of PTPN22 isoforms is shown in B. Statistical significance was determined
with Student’s t test. ns stands for not significant. *P <0.05; **P <0.005.
Figure 5 The level of protein tyrosine phosphatase, non-receptor type 22 (PTPN22) is negatively correlated with the Systemic Lupus
International Collaborating Clinics/American College of Rheumatology Damage Indiex (SLICC). Transcript level of total PTPN22 (A) and
PTPN22.2 (B) in peripheral blood of patients with lupus described in Figure 4 was plotted against SLICC. Correlation was analyzed with a non-parametric
Spearman test and adjusted for covariates including gender, age, age of disease onset, duration of disease, and race (white or non-white).
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very likely affects the expression of all isoforms. Therefore,
the 110 kD broad protein band, which was reduced by
approximately 80% by the PTPN22 siRNA, is very
likely composed of PTPN22.1, PTPN2.2, PTPN22.5, and
PTPN22.8, which have comparable molecular weight. The
smaller protein species very likely include Lyp2 and/or
yet-to-be-discovered isoforms. However, there is no other
isoform-specific antibody, and it is still unclear whether
the other non-full-length PTPN22 proteins also exist in
human cells. To further confirm their existence, we de-
signed a single siRNA targeting the 3′ end of Lyp2. This
siRNA is expected to suppress the expression of Lyp2 and
any yet-to-be-discovered isoforms sharing the 3′ end with
Lyp2, but not the other isoforms shown in Figure 1A.
Indeed, expression of the siLyp2 in Jurkat cells led to the
disappearance of the smaller PTP22 protein species in-
cluding one with a molecular weight comparable to that
of Lyp2 (Figure 1D, the left panel), but had a negligible
effect on the level of the dominant 110 kD protein band
(Figure 1D, the right panel). This result strongly indicates
that, in addition to PTPN22.6, endogenous Lyp2 protein
is also present in human Tcells.
Expression of PTPN22 isoforms in human PBMC
We set out to compare the expression kinetics of each
isoform in human T cells. We isolated primary Th cells
from the peripheral blood of healthy donors and sti-
mulated the cells with anti-CD3/anti-CD28 for various
periods of time. cDNA was prepared from the stimu-
lated cells and subjected to real-time PCR. We designed
three pairs of primers specific for PTPN22.2, Lyp2, and
PTPN22.6. (Figure 1A). However, PTPN22.1, PTPN22.5,
and PTPN22.8 do not have an isoform-specific splice
junction. We therefore designed three additional pairs of
primers. One pair targeted the 5′ region shared by all
isoforms and was used to represent ‘total’ PTPN22
expression. The second pair of primers (PTPN22.5/6)
recognized both PTPN22.5 and PTPN22.6 but not other
isoforms. The third pair of primers (PTPN22.7/8) was
specific to the splice junction shared only by PTPN22.7
and PTPN22.8. We measured the level of PTPN22 iso-
forms in Th cells obtained from three healthy donors.
The data on the level of total PTPN22 and PTPN22.6
were previously reported but were included here for the
purpose of comparison. We found that the level of ‘total’
transcript dropped by approximately 50% 24 hours after
stimulation and then gradually increased and eventually
peaked 5 days after stimulation (Figure 2A). The level of
the total PTPN22 transcript was approximately 10 to 50
times more than that of the non-full-length isoforms.
The expression kinetics of the non-full-length PTPN22
isoforms can be roughly divided into two groups. The
first group including Lyp2 and PTPN22.2 displayed a
kinetics similar to that of the total transcript (Figure 2A).
In contrast, the transcript level of the second group in-
cluding PTPN22.5/6, PTPN22.6, and PTPN22.7/8 was
not induced throughout the whole course. None of the
PTPN22 transcripts were detected at any significant
level in HT-29 cells, which expressed no PTPN22 (data
not shown). As the transcript levels of the non-full-
length isoforms were much lower than that of the total
PTPN22 transcript, we believe that the full-length
PTPN22 (that is PTPN22.1) is the main contributor to
the level of the total PTPN22 transcript. Indeed, the mo-
lecular weight of a dominant protein band detected with
anti-PTPN22 on Western blotting corresponded to that
of PTPN22.1 (Figure 2B). The level of PTPN22.1 protein
in primary Th cells also gradually increased after stimu-
lation, a kinetics similar to that of the total transcript of
PTPN22 with the exception of no reduction in the levels
at 24 hours.
PTPN22 is also expressed in myeloid cells including
macrophages. Macrophages can be divided into two
major functional subsets: classically activated macro-
phages (M1 cells) and alternatively activated macro-
phages (M2 cells). We have recently shown that resting
macrophages expressed a basal level of total PTPN22
and that the level stayed relatively unchanged in M1
cells [9]. In contrast, the expression of total PTPN22
was induced in M2 cells to a level three to four times
higher than that of resting or M1 cells. To examine the
expression of PTPN22 isoforms in macrophages, we
quantified the transcript level of PTPN22 isoforms in
macrophages from seven healthy donors. We found that
the levels of Lyp2, PTPN22.2, PTPN22.5/6, PTPN22.6,
and PTPN22.7/8 were very comparable among resting,
M1, and M2 macrophages (Figure 2C). Thus, the in-
crease in total PTPN22 observed in M2 cells mainly
comes from PTPN22.1. Taken together, our data indicate
that the level of PTPN22 isoforms varies significantly
among cells types and in response to different stimuli.
Subcellular localization and function of PTPN22 isoforms
PTPN22 contains a NLS at its N-terminus and is also
present in the nucleus of macrophage and T cells [9].
This NLS is present in all isoforms. To further examine
the subcellular localization of PTPN22 isoforms, we
expressed each isoform in 293 cells and separately ex-
amined the cytoplasmic and nuclear extract of the
transfected cells with Western blotting. As expected,
PTPN22.1 was detected in both the cytoplasm and the
nuclei of the transfected cells (Figure 3A). A similar
pattern of subcellular localization was observed for
Lyp2, PTPN22.2, and PTPN22.5. Interestingly, we de-
tected PTPN22.6 and PTPN22.8 only in the cytoplasm
but not in the nucleus of the transfected cells, sugges-
ting the presence of an additional and essential NLS
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isoforms.
PTPN22.6 can act as a dominant negative variant of
PTPN22.1. But the function of the other isoforms is still
unclear. We therefore examined the effect of the other
isoforms on NFAT-driven luciferase activity. As expected,
overexpression of PTPN22.1 in Jurkat cells suppressed
NFAT-dependent luciferase activity by approximately 50%.
Interestingly, Lyp2, PTPN22.2, PTPN22.5, and PTPN22.8,
despite missing parts of the PTP domain, also had the
same effect (Figure 3B). There was no statistically signi-
ficant difference among these isoforms even after adjust-
ment for the protein level. In addition, a catalytic dead
mutant of mouse PTPN22, which contains D195A and
C227S mutations [4], had no impact on NFAT activity
(Additional file 1), further indicating that these isoforms
are still catalytic active. In contrast, expression of
PTPN22.6 resulted in a subtle but statistically significant
increase in NFAT activity. This result was reported before
but was included for comparison [13].
Expression of PTPN22 isoforms in healthy and SLE
populations
To determine whether the expression of PTPN22 iso-
forms was altered in SLE patients and whether the level
of PTPN22 isoforms was correlated with clinical features
of SLE, we quantified the transcript level of each isoform
in the peripheral blood of 15 healthy donors and 49 pa-
tients with SLE. The demographic characteristics of the
study subjects are shown in Table 1. All healthy indi-
viduals were female, but two of the 49 patients with
lupus were male. The average ages were 46.2 years and
48.8 years for the healthy and SLE groups, respectively.
We found that the transcript level of all isoforms ex-
cept PTPN22.6 was approximately two to three times
higher in the SLE group compared to that of the healthy
group (Figure 4A). The level of PTPN22.6 was low but
comparable in both groups. In addition, the transcript
level of Ets-1, a gene that is associated with SLE in
Asians [25-27], was also comparable between the two
groups (Additional file 2), indicating that the aberrant
expression of PTPN22 is not a non-specific event. To
determine whether there was preferential expression of
any one of the isoforms in SLE patients, we calculated
the percentage of each isoform against the total PTPN22
transcript. After deducing the percentage of Lyp2,
PTPN22.2, PTPN22.5/6, PTPN22.6, and PTPN22.7/8,
the remainder was designated as ‘others’, which we
believe was made up of mainly PTPN22.1. We found
that SLE patients, compared to healthy individuals, had
a modest but statistically significant increase in the
percentage of Lyp2 and PTPN22.2 but a reciprocal de-
crease in the percentage of PTPN22.5/6 and the ‘others’
(Figure 4B). There was no difference in the percentage
of PTPN22.6 and PTPN22.7/8. Thus, patients with SLE
had not only overexpression of PTPN22 but also an
alteration in the relative level of PTPN22 isoforms.
We subsequently examined whether there was any
correlation between the transcript level of PTPN22 and
clinical parameters of lupus. We found no correlation
between total PTPN22 level and SLEDAI, level of anti-
nuclear antibody, or level of anti-double-stranded DNA.
However, a significant negative correlation between
SLICC-DI and the total transcript level of PTPN22 was
observed (Figure 5A). We then examined whether any of
the non-full-length isoforms was also negatively cor-
related with SLICC-DI. We found that the level of
PTPN22.2 but not other non-full-length isoforms also
showed a negative correlation with SLICSS-DI even after
adjustment for covariates including gender, age, age of
disease onset, duration of disease, and race (white or
non-white) (Figure 5B).
Discussion
The collection of PTPN22 isoforms has expanded sig-
nificantly over the past few years. During the preparation
of this manuscript, another isoform lacking exon 15 was
deposited in the NCBI database as isoform 3 (tentatively
called PTPN22.3), which is also present in chimpanzees
[28]. The expression of PTPN22.3 in different types of
hematopoietic cells and its effect on NFAT activity have
yet to be examined. Despite the publication of the clo-
ning of Lyp2, we would like to cautiously point out that
the existence of this transcript has yet to be confirmed.
The conclusion that this isoform exists is based on the
identification of a cDNA fragment corresponding to its
unique 3′ end. This isoform was then deduced from se-
veral overlapping cDNA fragments [1]. However, there is
no full-length cDNA clone in the NCBI database mat-
ching Lyp2. In addition, we were unable to amplify the
entire transcript of Lyp2 from Jurkat cells. Instead, we
recently amplified an intact and novel transcript from
Jurkat cells that shares the 3′ end with Lyp2 but con-
tains a deletion in the PTP domain (data not shown). It
Table 1 Demographic characteristics of the study subjects
Healthy With systemic lupus erythematosus
Number and gender 15 F 47 F and 2 M
Age (years) 46.2±5.2 48.8±12.5
Ethnicity 9 Caucasians, 4 blacks, 1 Asians, and 1 Asian/Caucasian 36 Caucasians, 4 blacks, 4 Asians, and 5 Hispanics
Chang et al. Arthritis Research & Therapy 2014, 16:R14 Page 9 of 12
http://arthritis-research.com/content/16/1/R14is very likely that there are other yet-to-be-discovered
isoforms sharing the 3′ end with Lyp2. This scenario is
consistent with the observation that the siLyp2 sup-
presses the expression of several PTPN22 protein spe-
cies (Figure 1D). Ultimately, mass spectrometry and/or
isoform-specific antibodies will be needed to confirm
the presence of non-full-length PTPN22 proteins in dif-
ferent types of immune cells.
With the exception of PTPN22.6, all isoforms examined
in this study are functionally interchangeable in suppres-
sing NFAT activity. However, the function of PTPN22 is
still poorly understood. For example, we recently found
that cytoplasmic PTPN22 suppresses M1 polarization,
whereas nuclear PTPN22 promotes M2 polarization of
macrophages [9]. PTPN22 is also expressed in neutrophils
and NK cells, and its function in these cells is largely un-
known. It is possible that the non-full-length isoforms,
each missing a part (or parts) of the PTPN22 protein and
some excluded from the nucleus, can also act as domi-
nant negative mutants of PTPN22.1 in other functional
readouts or immune cells. Thus, the overall activity of
PTPN22 is determined by not only the total level of
PTPN22 but also by the functional balance among all
isoforms.
The functional balance of PTPN22 isoforms may cri-
tically influence the impact of the C1858T SNP. It is still
poorly understood how the C1858T SNP increases the
risk of SLE and RA but lowers the risk of Crohn’s dis-
ease. There are conflicting data on the impact of this
SNP on the responsiveness of human T cells to stimula-
tion. We have previously shown that the effect of the
C1858T SNP on cytokine production in Th cells is
isoform dependent [13]. The R-to-W conversion in the
context of PTPN22.1 further weakened NFAT activity
and IL-2 production. In contrast, the R-to-W conversion
in the context of PTPN22.6 enhanced IL-2 production.
If the other non-full-length PTPN22 isoforms also have
a function different from that of PTPN22.1, then the
cumulative impact of the C1858T SNP can be compli-
cated and highly dependent on the portfolio of PTPN22
isoforms. This scenario may explain the conflicting data
described above.
Why do SLE patients express a higher level of PTPN22?
The expression of PTPN22 is induced in activated T cells
and M2 macrophages. Th and macrophages of patients
with lupus are likely activated and express a higher level
of PTPN22. The whole blood samples stored in the BWH
Lupus Biobank did not allow separate quantification of
PTPN22 levels in each type of blood cells. Some types of
blood cells, such as T cells, may express more PTPN22
than other types of blood cells, such as macrophages. An
expansion of the high PTPN22-expressing cells, but not
necessarily an increase in their status of activation, may
also contribute to the high level of PTPN22 observed in
the whole blood of patients with SLE. Identifying the
PTPN22-expressing cells responsible for the higher
PTPN22 level in the peripheral blood of patients with SLE
may shed light on the pathogenesis of this disease. It is
also intriguing to notice that patients with SLE not only
have a high level of PTPN22 but also have an altered port-
folio of PTPN22 isoforms. They express more Lyp2 and
PTPN22.2 at the expense of PTPN22.1 compared to
healthy individuals. The clinical significance of such an
alteration in the portfolio of PTPN22 isoforms has yet to
be determined.
A recent paper by Ronninger et al. reported a trend
suggesting that the combined transcript level of long
PTPN22 isoforms including PTPN22.1, PTPN22.2, and
PTPN22.3 was higher in PBMC of patients with RA than
healthy controls [29]. Although this trend is consistent
with the data shown in Figure 4, their data also showed
a trend of lower Lyp2 in patients with RA. In addition,
the ratio of long PTPN22 to Lyp2 was significantly
higher in patients with RA. We, however, found that the
level of Lyp2 was higher while the ratio of long PTPN22
to Lyp2 was lower in our patients with lupus. This dis-
crepancy may originate from fundamental differences in
the pathogenesis between RA and lupus. In addition, the
primers and probe used to detect long PTPN22 isoforms
in Ronninger’s paper target their 3′ end and will not
detect PTPN22.5, PTPN22.6, and other yet-to-be-disco-
vered isoforms sharing the 3′ end with PTPN22.5 and
PTPN22.6. The difference in primers used may also
explain why the ratio of long PTPN22 to Lyp2 is much
lower in Ronninger’s study (1 to 1.5) than ours (20 to 30).
Our calculated ratio is more consistent with the data
shown in Figure 1D.
McKinney et al. recently showed that a higher level of
PTPN22, along with a low level of ITGA and Notch1 in
CD8+ T cells but not PBMC, was associated with a poor
prognosis in SLE and anti-neutrophil cytoplasmic anti-
body (ANCA)-associated vasculitis [30]. The molecular
explanation for this correlation is still lacking. The level
of PTPN22 in McKinney’s study was indirectly deter-
mined by gene chip, which is not specific to any of the
PTPN22 isoforms. It will be interesting to know whether
such an association could be observed in PBMC if the
expression of each of the PTPN22 isoforms was mea-
sured. Given the McKinney’s report, it is surprising to
find in our study that the level of PTPN22 in peripheral
blood was not correlated with SLE disease activity
(SLEDAI), but actually was negatively correlated with
SLICC-DI. SLICC-DI is usually associated with disease
duration. However, we found no correlation between
PTPN22 level and disease duration in our SLE popula-
tion. It is possible that the negative correlation is attri-
buted to damage to one organ. The SLICC-DI in our
SLE population was relatively low. However, we did
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PTPN22 levels and damage to the musculoskeletal sys-
tem (data not shown). More patients will be needed to
establish such a negative association.
We do not have a biological explanation for the nega-
tive correlation between PTPN22 level and SLICC-DI at
this moment. There was a substantial drop in the level
of PTPN22 in patients with a SLICC-DI equal to or
higher than three. We saw no obvious difference in the
portfolio of PTPN22 isoforms in this small group of pa-
tients (N=12) compared to the other patients with SLE.
Deficiency of PTPN22 has been shown to lead to hyper-
activation of lymphocytes and overexpression of in-
flammatory cytokines in macrophages [8,9]. Thus, a
r e d u c t i o ni nt h el e v e lo fP T P N 2 2a sd e t e c t e di nt h o s e
12 patients can be proinflammatory, thereby resulting in
more organ damage. This hypothesis remains to be
confirmed.
Conclusions
This paper is the first to examine and compare the expres-
sion, subcellular localization, and function of various
isoforms of PTPN22, a gene that is strongly associated
with several rheumatic diseases. Human PTPN22 can be
expressed in several isoforms, and some of the isoforms
are also present in the nucleus due to at least two essential
nuclear localization signals. The expression profile of
PTPN22 isoforms varies among cell types, and is altered
in patients with lupus. In addition, the levels of total
PTPN22 and one of the isoforms are negatively correlated
with SLICC-DI scores. Future studies investigating the
molecular basis of this negative correlation will provide
important insight into the pathogenesis of SLE.
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